BayCare aligns with Northwestern and its renowned medical school
BayCare has signed a deal with Northwestern Medicine, a collaboration that officials say is a critical step in the nonprofit's bid to expand its academic health system
Northwestern is a nationally renowned academic health system through its partnership with the Northwestern University Feinberg School of Medicine. Its deal with BayCare will provide more access to advanced medical treatments, expand clinical research and improve training and education for current and future physicians in the Tampa Bay region, officials said.
'This isn't the beginning, it's the next step in a journey we've been focused on for years,' BayCare President and CEO Stephanie Conners said in a news release. 'West Central Florida deserves more access to academic medicine and by entering into a strategic collaboration with Northwestern Medicine, we will accelerate our trajectory as an academic health system.'
Academic health systems are designed to innovate and produce leading edge treatments by integrating clinical care with research and education. Locally, Tampa General Hospital bills itself as the region's only academic health system through its 50-year partnership with USF Health Morsani College of Medicine.
BayCare already partners with the University of South Florida and Florida State University for sponsorship of residency programs in family and sports medicine. The collaboration with Northwestern will lead to new educational and training opportunities, making BayCare a more attractive option for physicians, residents, and students, officials said.
Headquartered in Chicago, Northwestern operates 11 hospitals and more than 200 diagnostic and out-patient centers. Its flagship facility, Northwestern Memorial Hospital, has been named to the Best Hospitals Honor Roll by U.S. News and World Report for 13 consecutive years.
The Feinberg School of Medicine received $742 million in research funding and awards in 2024, with 15 of its departments among the top 20 National Institute of Health award recipients.
'We are focused on collaborating with likeminded organizations that are driven by providing patients with greater access to world-class compassionate care, closer to where they live and work,' Northwestern President and CEO Howard Chrisman said in a statement. 'By collaborating with BayCare, we have the opportunity to train and educate the next generation of medical professionals and transform the clinical offerings to patients in West Central Florida.'
BayCare, which operates 16 hospitals and more than a hundred clinics in the region, plans to house its academic and research operations in a 36-acre office park that it purchased for $145 million earlier this year.
The site, adjacent to St. Joseph's, St. Joseph's Children's and St. Joseph's Women's hospitals in West Tampa, will be named the BayCare Academic Health and Research Corridor.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
BayCare aligns with Northwestern and its renowned medical school
BayCare has signed a deal with Northwestern Medicine, a collaboration that officials say is a critical step in the nonprofit's bid to expand its academic health system Northwestern is a nationally renowned academic health system through its partnership with the Northwestern University Feinberg School of Medicine. Its deal with BayCare will provide more access to advanced medical treatments, expand clinical research and improve training and education for current and future physicians in the Tampa Bay region, officials said. 'This isn't the beginning, it's the next step in a journey we've been focused on for years,' BayCare President and CEO Stephanie Conners said in a news release. 'West Central Florida deserves more access to academic medicine and by entering into a strategic collaboration with Northwestern Medicine, we will accelerate our trajectory as an academic health system.' Academic health systems are designed to innovate and produce leading edge treatments by integrating clinical care with research and education. Locally, Tampa General Hospital bills itself as the region's only academic health system through its 50-year partnership with USF Health Morsani College of Medicine. BayCare already partners with the University of South Florida and Florida State University for sponsorship of residency programs in family and sports medicine. The collaboration with Northwestern will lead to new educational and training opportunities, making BayCare a more attractive option for physicians, residents, and students, officials said. Headquartered in Chicago, Northwestern operates 11 hospitals and more than 200 diagnostic and out-patient centers. Its flagship facility, Northwestern Memorial Hospital, has been named to the Best Hospitals Honor Roll by U.S. News and World Report for 13 consecutive years. The Feinberg School of Medicine received $742 million in research funding and awards in 2024, with 15 of its departments among the top 20 National Institute of Health award recipients. 'We are focused on collaborating with likeminded organizations that are driven by providing patients with greater access to world-class compassionate care, closer to where they live and work,' Northwestern President and CEO Howard Chrisman said in a statement. 'By collaborating with BayCare, we have the opportunity to train and educate the next generation of medical professionals and transform the clinical offerings to patients in West Central Florida.' BayCare, which operates 16 hospitals and more than a hundred clinics in the region, plans to house its academic and research operations in a 36-acre office park that it purchased for $145 million earlier this year. The site, adjacent to St. Joseph's, St. Joseph's Children's and St. Joseph's Women's hospitals in West Tampa, will be named the BayCare Academic Health and Research Corridor.
Newsweek
18 hours ago
- Newsweek
Viral Beauty Routines Are Damaging Tween and Teen Skin, Study Warns
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. "Get ready with me" videos are overflowing on TikTok, drawing millions to watch influencers and the like walk through their skincare routines. But lately, a new wave of content creators is entering the frame: middle schoolers or even children as young as seven layering serums, eye creams and exfoliants onto already delicate, youthful skin. Now, new research has confirmed these types of videos can put teens at risk of lifelong skin allergy. Young teenager recording 'Get Ready With Me' beauty blog from cozy bedroom applying clay facial mask. Young teenager recording 'Get Ready With Me' beauty blog from cozy bedroom applying clay facial mask. Mariia Vitkovska The new peer-reviewed study from Northwestern Medicine, published today on June 9 in Pediatrics, is raising red flags about the popular trend of teen skincare routines shared on social media. The study is the first of its kind to examine the dermatological and psychological risks tied to these viral beauty regimens. Authors found girls between the ages of seven and 18 are applying an average of six different skincare products daily, with some layering more than a dozen. "It's problematic to show girls devoting this much time and attention to their skin," said corresponding author Dr. Molly Hales, a postdoctoral research fellow and board-certified dermatologist in the department of dermatology at Northwestern University Feinberg School of Medicine. The financial cost is also concerning. The average teen skincare routine costs $168 a month, according to the study, with some reaching upward of $500. Despite the hype, the routines often neglect the basics: only 26 percent of daytime regimens included sunscreen—a critical oversight, especially for developing skin. Yet it's not just money being wasted. The study found that the top-viewed skincare videos featured an average of 11 potentially irritating active ingredients. This cocktail of acids, retinoids and fragrances increases the risk of allergic contact dermatitis—a lifelong skin allergy that can permanently restrict a person's use of certain soaps, shampoos and cosmetics. "That high risk of irritation came from both using multiple active ingredients at the same time, such as hydroxy acids, as well as applying the same active ingredient unknowingly over and over again when that active ingredient was found in three, four, five different products," Hales said. In one analyzed video, a content creator applied 10 separate products in just six minutes. By the end of the clip, her face was visibly red and irritated. "As she's applying the products, she begins to express discomfort and burning, and in the final few minutes, she develops a visible skin reaction," said senior author Dr. Tara Lagu, adjunct lecturer of medicine and medical social sciences at Feinberg and a former Northwestern Medicine hospitalist. The researchers also observed an unsettling pattern in the aesthetics and messaging of these viral videos. "We saw that there was preferential, encoded racial language in some cases that really emphasized lighter, brighter skin," Lagu said. "I think there also were real associations between use of these regimens and consumerism." The videos tend to offer little to no health benefit for the children watching them, researchers concluded. Yet they're virtually impossible for parents or pediatricians to monitor, thanks to the untrusted algorithms that power TikTok's "For You" page. "We're setting a very high standard for these girls," Hales said. "The pursuit of health has become a kind of virtue in our society, but the ideal of 'health' is also very wrapped up in ideals of beauty, thinness and whiteness. The insidious thing about 'skin care' is that it claims to be about health." Funding for the study was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (grant number 5T32AR060710-11). Other Northwestern authors include Drs Amy Paller and Walter Liszewski, and medical student Sarah Rigali. Newsweek reached out to TikTok via email on 06/06/2025.
New York Post
2 days ago
- New York Post
Menopause drug might prevent breast cancer and treat hot flashes, research finds
A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, 'significantly reduced' breast tissue cell growth, which is a major indicator of cancer progression. Advertisement A phase 2 clinical trial included 141 post-menopausal women who had been diagnosed with ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, according to a press release from Northwestern. This non-invasive breast cancer affects more than 60,000 American women each year, often leading to an outcome of invasive breast cancer. The women were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Duavee is a conjugated estrogen/bazedoxifene (CE/BZA) drug, which combines estrogen with another medication that minimizes the potential harmful side effects of the hormone. Advertisement 'The key takeaway from the study is that CE/BZA slows the growth (proliferation) of cells in milk ducts of DCIS that expressed the estrogen receptor significantly more than placebo,' Dr. Swati Kulkarni, lead investigator and professor of breast surgery at Northwestern University Feinberg School of Medicine, told Fox News Digital. 5 New research from Northwestern University found that the drug Duavee 'significantly reduced' breast tissue cell growth, a major indicator of cancer progression. Marko Geber – Another major finding is that the quality of life did not differ significantly between the two groups, but patients who took the CE/BZA reported fewer hot flashes during the study, she noted. 'This would be expected, as the drug is FDA-approved to treat hot flashes.' Advertisement Kulkarni presented the study last week at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. 5 The women in the study were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Gorodenkoff – 5 Those who took the drug reported fewer hot flashes during the study. fizkes – The findings are preliminary and have not yet been published in a medical journal. Advertisement 'What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer,' said the doctor, who is also a Northwestern Medicine breast surgeon. Women who face a higher risk of breast cancer — including those who have experienced 'high-risk lesions' — and who also have menopausal symptoms are most likely to benefit from the drug, according to Kulkarni. 'These women are typically advised against standard hormone therapies, leaving them with few menopausal treatment options,' the release stated. Study limitations The researchers said they are 'encouraged' by these early results, but more research is required before the medication can be considered for approval as a breast cancer prevention mechanism. 'Our findings suggest that CE/BZA may prevent breast cancer, but larger studies with several years of follow-up are needed before we would know this for sure,' Kulkarni told Fox News Digital. Dr. Sheheryar Kabraji, chief of breast medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, was not involved in the study but commented on the findings. 5 'What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer,' Dr. Swati Kulkarni said. sarayutsridee – Advertisement 'While intriguing, this study is highly preliminary, and more research will be needed before we can conclude that conjugated estrogen/bazedoxifene (CD/BZA), a form of the hormone estrogen commonly prescribed to address symptoms of menopause, prevents invasive breast cancer or is effective at reducing cancer risk,' he told Fox News Digital. Kabraji also noted that the study focused on reducing levels of one specific protein, 'which does not always predict reduced recurrence of breast cancer.' 'This study did not directly show that CE/BZA treatment reduces the risk of DCIS recurrence or development of invasive cancer,' he noted. 5 According to Kulkarni,'larger studies with several years of follow-up are needed' to confirm that the drug prevents breast cancer. Science RF – Advertisement 'Importantly, however, patients who received this therapy experienced no worsening of quality of life, and saw improvement in vasomotor symptoms, such as hot flashes. If found to be effective in preventing breast cancer, CE/BZA is likely to have fewer side effects than current medications used for breast cancer prevention.' Lead researcher Kulkarni emphasized that this medication is not for the treatment of invasive breast cancer or DCIS. 'Right now, we can say that women who are concerned about their risk of developing breast cancer can consider this medication to treat their menopausal symptoms,' she added.
